SCHEMBL6693538

SCHEMBL6693538

COC(=O)c1cccc2c1c1c(n2Cc2c(Cl)cccc2Cl)CCCC1=O

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HDAC1 Q13547 3/20 0.42
HDAC6 Q9UBN7 3/20 0.42
CYP3A4 P08684 2/20 0.40
CYP2C9 P11712 2/20 0.40
CYP2C19 P33261 2/20 0.40
CYP1A2 P05177 1/20 0.40
NPSR1 Q6W5P4 1/20 0.40
KDM4E B2RXH2 4/20 0.39
ALDH1A1 P00352 6/20 0.37
MAPT P10636 2/20 0.37
TSHR P16473 1/20 0.37
KMT2A Q03164 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PLA2G2A P14555 2/20 0.36
GAA P10253 1/20 0.36
ALOX15 P16050 1/20 0.36
HSD17B10 Q99714 1/20 0.36
CSNK2A2 P19784 4/20 0.36
CSNK2B P67870 4/20 0.36
CSNK2A1 P68400 4/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6694051 0.91 HDAC1 (0.44) HDAC1HDAC6CYP3A4CYP2C9CYP2C19
SCHEMBL6689259 0.88 HDAC1 (0.40) HDAC1HDAC6KDM4EALDH1A1MAPT
SCHEMBL5207833 0.88 HDAC1 (0.51) HDAC1HDAC6KDM4EKMT2ACSNK2A2
SCHEMBL6693631 0.85 HDAC1 (0.45) HDAC1HDAC6KDM4EMAPTPLA2G2A
SCHEMBL6774729 0.84 HDAC1 (0.45) HDAC1HDAC6NPSR1KDM4EALDH1A1
SCHEMBL6689321 0.84 HDAC1 (0.42) HDAC1HDAC6NPSR1KDM4EALDH1A1
SCHEMBL6693115 0.83 FABP3 (0.45) HDAC1HDAC6CYP2C9CYP2C19CYP1A2
SCHEMBL6691809 0.83 HDAC1 (0.44) HDAC1HDAC6NPSR1KDM4EMAPT
SCHEMBL6691242 0.82 HDAC1 (0.46) HDAC1HDAC6KDM4EMAPTPLA2G2A
SCHEMBL6692697 0.82 HDAC1 (0.41) HDAC1HDAC6KDM4EALDH1A1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-0952149-B1 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors LILLY CO ELI (US) 2004-06-09 EP disclosed
US-6713645-B1 INHIBITING SPLA2 MEDIATED RELEASE OF FATTY ACIDS FOR TREATMENT OF CONDITIONS SUCH AS SEPTIC SHOCK ELI LILLY AND COMPANY 2004-03-30 US disclosed
US-6177440-B1 THERAPY FOR SEPSIS SHOCK; PHOSPHOLIPASE INHBITOR ELI LILLY AND COMPANY 2001-01-23 US disclosed
EP-0952149-A2 Substituted carbazoles, process for their preparation and their use as sPLA2 inhibitiors ELI LILLY AND COMPANY (US) 1999-10-27 EP disclosed